DEFENDER PHARMACEUTICALS, INC.

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2017–2025

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2025	—	1	1
2024	—	4	1
2023	—	5	1
2022	—	4	1
2021	—	4	1
2020	—	4	1
2019	—	4	1
2018	—	5	2
2017	—	4	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
AMERICAN DEFENSE INTERNATIONAL INC	—	28
THE GALLAGHER GROUP, LLC	—	7

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	21
SENATE	15
Defense, Dept of (DOD)	6
Veterans Affairs, Dept of (VA)	5

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Defense	Defense	29
Veterans	Veterans	5

Bills Explicitly Cited (7)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 2670118th Congress

National Defense Authorization Act for Fiscal Year 2024

2024 · first_quarter · Firm: AMERICAN DEFENSE INTERNATIONAL INC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2670: National Defense Authorization Act (NDAA), provisions related to scopolamine research.

Client expense: — · Firm income: $5,000

Matched citations: H.R. 2670

H.R. 2670118th Congress

National Defense Authorization Act for Fiscal Year 2024

2023 · fourth_quarter · Firm: AMERICAN DEFENSE INTERNATIONAL INC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2670: National Defense Authorization Act (NDAA), provisions related to scopolamine research.

Client expense: — · Firm income: —

Matched citations: H.R. 2670

H.R. 5515115th Congress

John S. McCain National Defense Authorization Act for Fiscal Year 2019

2018 · second_quarter · Firm: THE GALLAGHER GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 5515 FY 2019 National Defense Authorization Act; Issues related to treatment of warfighters for motion sickness.

Client expense: — · Firm income: $15,000

Matched citations: H.R. 5515

H.R. 5515115th Congress

John S. McCain National Defense Authorization Act for Fiscal Year 2019

2018 · first_quarter · Firm: THE GALLAGHER GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 5515 FY 2019 National Defense Authorization Act; Issues related to treatment of warfighters for motion sickness.

Client expense: — · Firm income: $15,000

Matched citations: H.R. 5515

Show 3 more cited filings

H.R. 2810115th Congress

National Defense Authorization Act for Fiscal Year 2018

2017 · fourth_quarter · Firm: THE GALLAGHER GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2810 FY 2018 National Defense Authorization Act; Issues related to treatment of warfighters for motion sickness.

Client expense: — · Firm income: $15,000

Matched citations: H.R. 2810

H.R. 2810115th Congress

National Defense Authorization Act for Fiscal Year 2018

2017 · third_quarter · Firm: THE GALLAGHER GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2810 FY 2018 National Defense Authorization Act; Issues related to treatment of warfighters for motion sickness.

Client expense: — · Firm income: $20,000

Matched citations: H.R. 2810

H.R. 2810115th Congress

National Defense Authorization Act for Fiscal Year 2018

2017 · second_quarter · Firm: THE GALLAGHER GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2810 FY 2018 National Defense Authorization Act; Issues related to treatment of warfighters for motion sickness.

Client expense: — · Firm income: $20,000

Matched citations: H.R. 2810

Source: Senate LDA

DEFENDER PHARMACEUTICALS, INC. — Lobbying Disclosure | Poliscope